Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Details

Ressource 1Download: 25999239.pdf (836.36 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_0B8C497CD972
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Journal
Swiss Medical Weekly
Author(s)
Samaras P., Bargetzi M., Betticher D.C., Duchosal M.A., Heim D., Hess U., Ketterer N., Lerch E., Matthes T., Mey U., Pabst T., Taverna C., Zander T., Renner C.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
145
Pages
w14100
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Abstract
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.
Keywords
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Monoclonal Gammopathy of Undetermined Significance/pathology, Multiple Myeloma/diagnosis, Multiple Myeloma/therapy
Pubmed
Web of science
Open Access
Yes
Create date
11/10/2016 15:29
Last modification date
20/08/2019 12:33
Usage data